Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel
NASDAQ:XCUR

Exicure 8/10/2026 Earnings Report

Exicure logo
$1.37 +0.03 (+1.86%)
As of 04:00 PM Eastern
ProfileEarnings HistoryForecast

Exicure EPS Results

Actual EPS
N/A
Consensus EPS
-$18.60
Beat/Miss
N/A
One Year Ago EPS
N/A

Exicure Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.64 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Exicure Announcement Details

Quarter
Date
8/10/2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Exicure Earnings Headlines

Exicure Announces Planned Issuance of Common Stock to Settle $1.0 Million Milestone Payment to GPCR Therapeutics
August 3, 2026  |  quiverquant.comQ
Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance
August 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/03/3337599/33289/en/exicure-to-settle-gpcr-therapeutics-clinical-milestone-payment-through-equity-issuance.html
The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits.tc pixel
August 10 at 1:00 AM  |  Porter & Company (Ad)
Exicure (XCUR) to Release Quarterly Earnings on Friday
July 31, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30931693
Exicure Reaches Preliminary Settlement in Derivative Lawsuits
July 9, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/XCUR/pressreleases/1140488/exicure-reaches-preliminary-settlement-in-derivative-lawsuits/
Exicure Announces Board and Committee Changes
June 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/30/3319699/33289/en/exicure-announces-board-and-committee-changes.html
See More Exicure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Exicure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Exicure and other key companies, straight to your email.

About Exicure

Exicure (NASDAQ:XCUR) is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology. By leveraging the unique structural properties of SNA constructs, Exicure aims to improve cellular uptake, enhance pharmacokinetics and reduce off‐target effects compared with traditional nucleic acid therapies.

Founded on technology originating from Northwestern University, Exicure is headquartered in Skokie, Illinois, where it conducts its research, preclinical studies and early‐stage development activities. The company completed its initial public offering on the Nasdaq exchange under the ticker XCUR and maintains a focused R&D footprint in the Chicago area.

Exicure collaborates with academic institutions and biopharmaceutical partners to advance its SNA platform and expand its therapeutic reach. Guided by a management team with deep expertise in biotechnology innovation, the company is working to translate its nanotechnology into novel treatments for patients with high‐unmet medical needs around the world.

View Exicure Profile
Earnings Tools